恩华药业
(002262)
| 流通市值：185.26亿 | | | 总市值：213.50亿 |
| 流通股本：8.82亿 | | | 总股本：10.16亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,510,888,789.07 | 5,697,633,044.59 | 4,145,463,113.62 | 2,763,398,107.9 |
| 营业收入 | 1,510,888,789.07 | 5,697,633,044.59 | 4,145,463,113.62 | 2,763,398,107.9 |
| 二、营业总成本 | 1,172,507,853.52 | 4,403,872,157.26 | 2,995,908,599.95 | 2,034,082,887.88 |
| 营业成本 | 382,394,251.04 | 1,506,540,854.61 | 1,088,072,577.17 | 759,967,077.35 |
| 税金及附加 | 18,793,598.74 | 75,294,786.77 | 54,093,907.54 | 36,781,715.1 |
| 销售费用 | 508,324,720.5 | 1,984,746,692.33 | 1,251,569,944.16 | 829,721,751.03 |
| 管理费用 | 74,119,812.54 | 258,761,700.49 | 178,668,886.12 | 114,894,739.91 |
| 研发费用 | 192,009,616.75 | 595,654,957.65 | 435,669,866.92 | 301,501,378.31 |
| 财务费用 | -3,134,146.05 | -17,126,834.59 | -12,166,581.96 | -8,783,773.82 |
| 其中:利息费用 | 674,955.24 | 4,025,878.2 | 3,215,924.43 | 2,342,331.06 |
| 其中:利息收入 | 4,267,518.34 | 22,254,894.13 | 16,196,021.76 | 11,591,935.22 |
| 加:投资收益 | 20,732,489.07 | 65,568,560.11 | 43,375,987.19 | 20,851,926.82 |
| 资产处置收益 | - | 293,968.27 | 30,193.71 | 28,993.71 |
| 资产减值损失(新) | -5,816,551.85 | -39,070,467.15 | -12,323,134.97 | -6,600,248.89 |
| 信用减值损失(新) | -18,071,053.83 | -34,573,542.62 | -16,040,020.85 | -16,646,330.25 |
| 其他收益 | 3,376,275.16 | 50,594,206.07 | 6,795,906.62 | 5,604,216.96 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 338,602,094.1 | 1,336,573,612.01 | 1,171,393,445.37 | 732,553,778.37 |
| 加:营业外收入 | 245,370.06 | 4,654,010.5 | 2,560,181.44 | 1,844,063.19 |
| 减:营业外支出 | 2,516,310.82 | 44,539,189.09 | 21,555,368.93 | 13,405,372.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 336,331,153.34 | 1,296,688,433.42 | 1,152,398,257.88 | 720,992,469.54 |
| 减:所得税费用 | 35,691,518.93 | 155,896,130.58 | 135,861,062.07 | 94,418,917.04 |
| 六、净利润 | 300,639,634.41 | 1,140,792,302.84 | 1,016,537,195.81 | 626,573,552.5 |
| 持续经营净利润 | 300,639,634.41 | 1,140,792,302.84 | 1,016,537,195.81 | 626,573,552.5 |
| 归属于母公司股东的净利润 | 300,705,740.93 | 1,143,564,427.44 | 1,020,107,123.07 | 628,920,268.32 |
| 少数股东损益 | -66,106.52 | -2,772,124.6 | -3,569,927.26 | -2,346,715.82 |
| (一)基本每股收益 | 0.3 | 1.13 | 1.01 | 0.62 |
| (二)稀释每股收益 | 0.3 | 1.13 | 1.01 | 0.62 |
| 八、其他综合收益 | - | -5,881,155.37 | - | - |
| 归属于母公司股东的其他综合收益 | - | -5,881,155.37 | - | - |
| 九、综合收益总额 | 300,639,634.41 | 1,134,911,147.47 | 1,016,537,195.81 | 626,573,552.5 |
| 归属于母公司股东的综合收益总额 | 300,705,740.93 | 1,137,683,272.07 | 1,020,107,123.07 | 628,920,268.32 |
| 归属于少数股东的综合收益总额 | -66,106.52 | -2,772,124.6 | -3,569,927.26 | -2,346,715.82 |
| 公告日期 | 2025-04-19 | 2025-03-29 | 2024-10-26 | 2024-07-31 |
| 审计意见(境内) | | 标准无保留意见 | | |